Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMI

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company’s phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Proactive: Hello you're watching Proactive, I'm joined by Immunic CEO Dr Daniel Vitt. Daniel, very good to speak with you. You reported positive data from your phase 2 EMPhASIS trial of vidofludimus calcium in relapsing remitting multiple sclerosis. The data shows a low rate of confirmed disability worse ...